# Molecular Mechanisms of Juvenile Nasopharyngeal Angiofibroma: A Narrative Review

## TL;DR

This paper reviews the biological mechanisms behind a rare tumor in teenage boys and explores potential targeted therapies to improve treatment outcomes.

## Contribution

The paper consolidates current knowledge on molecular pathways and biomarkers in juvenile nasopharyngeal angiofibroma, highlighting opportunities for targeted therapies.

## Key findings

- Key molecular drivers like HIF-1α, VEGF, and β-catenin are involved in tumor growth and angiogenesis.
- Hormonal influences, including androgens and estrogen, play a role in tumor progression.
- Preclinical studies suggest targeted therapies can reduce tumor vascularity, but clinical translation faces challenges like drug resistance.

## Abstract

JNA is a rare, benign but highly vascular tumor that mostly affects teenage boys. Surgery cures most patients, yet heavy bleeding during operations and tumor regrowth remain major problems. This review brings together what is known about the biological signals that drive JNA, including pathways that promote new blood vessel formation, cell growth, and hormone-related regulation that may explain its age and sex patterns. We outline how these pathway hubs could help prioritize practical biomarkers and support the development of targeted medicines, either to reduce blood supply before surgery or to treat stubborn or recurrent disease.

Juvenile nasopharyngeal angiofibroma (JNA), a rare vascular tumor in adolescent males, involves dysregulated angiogenesis and hormonal interplay. Key molecular drivers include HIF-1α, VEGF, bFGF, and β-catenin, promoting tumor growth via pathways like Wnt/β-catenin and Ras signaling. Androgens and estrogen modulate progression, though mechanisms remain debated. Targeted therapies reduce tumor proliferation and vascularity in preclinical studies, yet clinical translation is hindered by drug resistance and inconsistent biomarker expression. Hormonal and MMP-targeted approaches also show potential but require validation. This review consolidates JNA’s molecular landscape, emphasizing the need for personalized strategies, biomarker refinement, and combination therapies to improve therapeutic outcomes for this challenging tumor.